Abstract CT064: Updated safety and efficacy results from a phase 1/2 study of nezastomig, a first-in-class co-stimulatory PSMA×CD28 bispecific antibody (bsAb), plus cemiplimab (anti-PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Bilal A. Siddiqui, Jingsong Zhang, Benedito A. Carneiro, Kevin K. Zarrabi, Mark N. Stein, David R. Wise, Edward P. Gelmann, Che-Kai Tsao, Gerald Falchook, Joseph W. Kim, Xin Gao, Przemyslaw W. Twardowski, Divya Rana, Fang Fang, Shilpa Govindraj, Jennifer S. Sims, Dimitris Skokos, Frank A. Seebach, Israel Lowy, Pradeep Thanigaimani, Matthew Ingham, Sabina Sandigursky, Elizabeth Miller
Institutions: The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Brown University, Lifespan, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, Columbia University Irving Medical Center, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, University of Arizona, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, HealthONE, Yale University, Harvard University, Massachusetts General Hospital, Saint John's Health Center, Regeneron (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409822311